Elicio Therapeutics (ELTX) Registration Filing summary

Management team and governance

• President & CEO is Robert Connelly, who also serves as the principal executive officer.

• Preetam Shah, Ph.D., M.B.A., is Chief Strategy and Financial Officer.

• Board includes directors with medical and business backgrounds, such as Julian Adams, Carol Ashe, Allen R. Nissenson, Yekaterina Chudnovsky, Robert R. Ruffolo Jr., Karen J. Wilson, and Jay Venkatesan.

• Directors and officers are covered by indemnification agreements and liability insurance, with protections extended for six years post-merger.

Risk factors and disclosures

• Indemnification for directors and officers is provided to the fullest extent permitted by Delaware law, including advancement of expenses and insurance coverage.

• Any amendments to indemnification or exculpation provisions are restricted for six years post-merger unless required by law.

• SEC may deem certain indemnification provisions unenforceable as contrary to public policy.

Offering details and pricing

• Registration statement filed on Form S-3 for a shelf offering, allowing securities to be offered from time to time after effectiveness.

• Estimated SEC registration fee is $55,240 and FINRA filing fee is $60,500; other expenses are not specified.

• Post-effective amendments will be filed as needed to update or remove unsold securities.